EMI1 is primarily used in cancer research to study and inhibit the EGFR (Epidermal Growth Factor Receptor) signaling pathway, which is often overactive in various types of cancers. By targeting this pathway, EMI1 helps researchers understand the mechanisms of tumor growth and test potential therapeutic strategies. It is particularly valuable in preclinical studies to evaluate the effectiveness of EGFR inhibition in slowing or stopping cancer cell proliferation. Additionally, EMI1 serves as a tool compound in drug discovery, aiding in the development of more potent and selective EGFR inhibitors for clinical use. Its application extends to exploring resistance mechanisms in cancer cells and identifying combination therapies to enhance treatment outcomes.